Back to search results

Cannabis Use in Black and White Cancer Patients

This study aims to understand how Black and White cancer patients use cannabis, opioids, and tobacco. Researchers want to see how cannabis use affects pain and other symptoms in people with solid tumor cancer. You might be able to join if you are 21 or older, are Black or White, have been diagnosed with a solid tumor cancer in the last three years, experience pain, and are currently taking opioids for pain. You also need to be using cannabis at least once a week or not using it at all for the past three months. The study will look at changes in cannabis use, patient-reported outcomes (how you feel), and opioid use over 12 months. The study is currently unclear about its recruitment status.

Study design
This is an observational study involving 600 participants. It will follow participants over time to see how cannabis use relates to their experiences.
What's involved
You will complete surveys and use a smartphone app for daily assessments of pain, cannabis, and opioid use for one week each month for 12 months. You will also have remote video/phone assessments 12 times over the 12-month period.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for 12 months after starting the study.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06037681

Cannabis Use and Outcomes in Black and White Patients With Cancer

Recruiting
Not specifiedAges 21–99Observational
State University of New York at Buffalo
~600 participants
Updated 2025-10-30 on ClinicalTrials.gov

At a glance

Recruiting sites
3 of 3 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change from baseline of Cannabis use
Measured over Baseline to 12 months
+2 more outcomes measured

Conditions

Cancer

Explore related trials

Solid Neoplasm

NCT06037681

Where you'd take part

This study runs at 3 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Thomas Jefferson University

    Philadelphia, Pennsylvaniastudy coordinator listed

    Recruiting

  • University at Buffalo

    Buffalo, New Yorkstudy coordinator listed

    Recruiting

  • University of Pennsylvania

    Philadelphia, Pennsylvaniastudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Salimah Meghani, PhD · PRINCIPAL_INVESTIGATOR · University of Pennsylvania
  • Brooke Worster, MD · PRINCIPAL_INVESTIGATOR · Thomas Jefferson University
  • Rebecca L Ashare, PhD · PRINCIPAL_INVESTIGATOR · University at Buffalo

Who to contact

Colleen Kilanowski, MS
[email protected]
716-829-5977
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

21 years or older
Black or white race
Solid tumor cancer within 3 years of enrollment
Cannabis use of at least once a week or non cannabis use for 3 months
experience pain but spend less than 50% in bed or chair
Prescribed or take opioid for at least 30 days for pain
Not pregnant or planning to become pregnant in the next 12 months
English speaking

Exclusion

Lymphoma, leukemia, and melanoma
CBD only use
Synthetic cannabis use in past 3 months = Prescribed Medically-prescribed synthetic cannabis (e.g., dronabinol \[Marinol, Syndros\], Epidiolex)
race other than Black or White

What this trial measures

  • Change from baseline of Cannabis useBaseline to 12 months

    descriptive statistics will be generated for all cannabis-related variables across time \[frequency of use, composition (ratio of THC:CBD), indication, source (medical vs. non-medical), and route (inhalation/oral/topical)\]. Statistical comparisons will be made across key demographics (e.g., age, education, sex, race), cancer-related variables including cancer treatment status (active vs. completed), and other factors such as duration of opioid use (30-90 days vs. \>90 days).ecological momentary assessment questions

  • Cannabis use and patient reported outcomes and opioid useBaseline to 12 months

    For all data collected via EMA (cannabis use, opioid use, pain severity, and pain-related function), data will be aggregated at the daily level (84 days of data). For data collected via monthly surveys (anxiety, sleep, QoL) and EMR and PDMP extraction, each timepoint of data collection will be used (10 total: Baseline, Months 1-6, 8, 10, 12). For all variables, change in PROs and opioid use will be tested using HLMs. First, nested model tests will be used to evaluate the shape of change in each outcome variable (e.g., linear, polynomial, piecewise, etc.) as well as relevant random effects. Next, cannabis use (level-2 predictor) will be introduced into the models and crossed with time. We will evaluate whether the shape of change for each outcome differs by cannabis use group.

  • Cannabis use moderate the associations between race and painBaseline to 12 months

    This will follow the same approach described for Aim 2 with the inclusion of race as a dummy coded level 2 predictor and crossing race with cannabis use and time to form interaction terms. Significant interaction terms will be probed following Preacher et al.131. African Americans are expected to experience higher levels of pain severity and less decline in pain severity over time, and we predict this disparity will be reduced among cannabis users.